ELEKT-D: Electroconvulsive Therapy (ECT) vs. Ketamine in Patients With Treatment Resistant Depression (TRD)
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Depression
- ECT
- Electroconvulsive Therapy
- Ketamine
- Major Depressive Disorder
- Major Depressive Episode
- Psychiatric Disorder
- Treatment Resistant Depression
- Unipolar Depression
- Type
- Interventional
- Phase
- Phase 2Phase 3
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: unblinded prospective randomized open-labelMasking: None (Open Label)Masking Description: Due to the nature of the study treatments it is not possible to blind patients or investigators.Primary Purpose: Treatment
Participation Requirements
- Age
- Between 21 years and 75 years
- Gender
- Both males and females
Description
Patients with treatment resistant depression who meet all inclusion criteria and do not meet any exclusion criteria will be randomized to either electroconvulsive therapy (ECT) three times per week or ketamine infusion two times per week. Patients will answer questionnaires about their symptoms prio...
Patients with treatment resistant depression who meet all inclusion criteria and do not meet any exclusion criteria will be randomized to either electroconvulsive therapy (ECT) three times per week or ketamine infusion two times per week. Patients will answer questionnaires about their symptoms prior to treatments. The acute treatment phase of the study will last three to five weeks. Depending on response to treatment, some patients will be followed for an additional six months.
Tracking Information
- NCT #
- NCT03113968
- Collaborators
- Patient-Centered Outcomes Research Institute
- Investigators
- Principal Investigator: Amit Anand, MD The Cleveland Clinic
Get Well Soon